Neurocrine Biosciences
NBIX
#1377
Rank
C$21.85 B
Marketcap
C$215.90
Share price
-3.84%
Change (1 day)
10.98%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): C$9.77

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is C$9.99. In 2025 the company made an earnings per share (EPS) of C$6.91 an increase over its 2024 EPS that were of C$4.85.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$9.7741.35%
2025C$6.9142.6%
2024C$4.8533.07%
2023C$3.6457.76%
2022C$2.3169.47%
2021C$1.36-78.21%
2020C$6.25990%
2019C$0.5781.82%
2018C$0.32-113.5%
2017C-$2.340.62%
2016C-$2.3257.28%
2015C-$1.4825.61%
2014C-$1.1818.84%
2013C-$0.99-1085.71%
2012C$0.10

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
C$1.02-89.81%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
C$8.39-16.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
C$44.29 343.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
C-$0.29-102.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
C-$2.91-129.12%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
C$7.43-25.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
C-$10.83-208.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
C$2.19-78.06%๐Ÿ‡ฌ๐Ÿ‡ง UK